Emily Sneed has been named chief nursing officer for Medical City Lewisville. Sneed began her HCA Healthcare career as a registered nurse at Medical City Plano in 2009 and most recently served as assistant chief nursing officer at Medical City Plano. She brings 17 years of nursing experience to this new role, along with various leadership roles, including nurse educator, assistant nurse manager, nurse manager, and nurse director. Sneed has been awarded the D Magazine Excellence in Nursing Award and is recognized as a DFW Great 100 Nurse.
Joint venture partners Remedy Medical Properties and Kayne Anderson Real Estate acquired specialty surgical hospital Baylor Scott & White Frisco Medical Center. This 161,264-square-foot, two-story, 68-bed specialty hospital is 100 percent occupied by Texas Health Ventures Group, a joint venture between Baylor Scott & White Health and United Surgical Partners International. BSW Frisco Medical Center features 11 operating rooms including two robotic surgery rooms. Hospital services include orthopedics, OB/GYN, labor delivery/NICU, urology, spine, radiology, and general surgery, as well as an emergency department and onsite pharmacy.
UT Southwestern researchers have found that children with preexisting health problems or who lived in the Southern United States had a higher risk for severe health outcomes from acute COVID-19 infections. The national study examined records from 165,437 children, aged 18 and younger who tested positive for COVID-19 between January 2020 and January 2022. About 1.8 percent were hospitalized without complication, 1.8 percent were admitted to intensive care or needed intensive respiratory support, and 31 children died. Children in the Southern United States were more than three times as likely to have more severe complications compared with other areas of the country. In addition to these findings, the researchers reported that multiple chronic medical conditions, such as heart disease and lung disease, were more than twice as likely to have severe complications following COVID-19 infection. This study was funded by the National Center for Advancing Translational Sciences of the National Institutes of Health.
AyuVis Research, Inc. has been selected to join BLUE KNIGHT, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. AyuVis is developing a new generation of immunotherapies, including AVR-48, that provide a well-balanced outcome where mild activation and controlled suppression of the immune system are needed to effectively treat disease, allowing the drug to control inflammation and infection. Additionally, AyuVis will participate in a virtual residency at JLABS at the Texas Medical Center in Houston to support the expansion of AyuVis’ drug development program and the pursuit of additional non-dilutive funding opportunities.
Author
